{"id":351903,"date":"2025-08-26T06:28:30","date_gmt":"2025-08-26T06:28:30","guid":{"rendered":"https:\/\/pocketoption.com\/blog\/how-to-buy-nurix-therapeutics\/"},"modified":"2025-08-26T06:28:30","modified_gmt":"2025-08-26T06:28:30","slug":"how-to-buy-nurix-therapeutics","status":"publish","type":"post","link":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-nurix-therapeutics\/","title":{"rendered":"Nurix Therapeutics, Inc. (NRIX) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Nurix Therapeutics, Inc. (NRIX) Hisse Senedi Yat\u0131r\u0131m\u0131"},"content":{"rendered":"<div id=\"root\"><div id=\"wrap-img-root\">text<\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>text<\/p>\n","protected":false},"author":129,"featured_media":334108,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[12837],"tags":[40],"class_list":["post-351903","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-signal","tag-signal"],"acf":{"h1":"Nurix Therapeutics, Inc. (NRIX) Hisseleri Nas\u0131l Al\u0131n\u0131r - Nurix Therapeutics, Inc. (NRIX) Hisse Senedi Yat\u0131r\u0131m\u0131","h1_source":{"label":"H1","type":"text","formatted_value":"Nurix Therapeutics, Inc. (NRIX) Hisseleri Nas\u0131l Al\u0131n\u0131r - Nurix Therapeutics, Inc. (NRIX) Hisse Senedi Yat\u0131r\u0131m\u0131"},"description":"Nurix Therapeutics (NRIX) hisselerine nas\u0131l yat\u0131r\u0131m yap\u0131laca\u011f\u0131n\u0131, g\u00fcncel fiyat analizini, 2025-2030 tahminlerini ve maksimum getiri i\u00e7in ad\u0131m ad\u0131m sat\u0131n alma talimatlar\u0131n\u0131 \u00f6\u011frenin.","description_source":{"label":"Description","type":"textarea","formatted_value":"Nurix Therapeutics (NRIX) hisselerine nas\u0131l yat\u0131r\u0131m yap\u0131laca\u011f\u0131n\u0131, g\u00fcncel fiyat analizini, 2025-2030 tahminlerini ve maksimum getiri i\u00e7in ad\u0131m ad\u0131m sat\u0131n alma talimatlar\u0131n\u0131 \u00f6\u011frenin."},"intro":"Biyoteknoloji inovasyonunun patlay\u0131c\u0131 potansiyelinden faydalanmay\u0131 m\u0131 d\u00fc\u015f\u00fcn\u00fcyorsunuz? Nurix Therapeutics, kanser tedavisinde devrim yaratabilecek protein y\u0131k\u0131m\u0131 teknolojisinin \u00f6nc\u00fcs\u00fcd\u00fcr. Analist hedefleri %195'in \u00fczerinde y\u00fckseli\u015f potansiyeli g\u00f6sterirken, bu hisse dikkat \u00e7ekmeyi hak ediyor. Mevcut fiyatland\u0131rmadan uzun vadeli b\u00fcy\u00fcme beklentilerine kadar her \u015feyi detayl\u0131ca inceleyelim.","intro_source":{"label":"Intro","type":"text","formatted_value":"Biyoteknoloji inovasyonunun patlay\u0131c\u0131 potansiyelinden faydalanmay\u0131 m\u0131 d\u00fc\u015f\u00fcn\u00fcyorsunuz? Nurix Therapeutics, kanser tedavisinde devrim yaratabilecek protein y\u0131k\u0131m\u0131 teknolojisinin \u00f6nc\u00fcs\u00fcd\u00fcr. Analist hedefleri %195'in \u00fczerinde y\u00fckseli\u015f potansiyeli g\u00f6sterirken, bu hisse dikkat \u00e7ekmeyi hak ediyor. Mevcut fiyatland\u0131rmadan uzun vadeli b\u00fcy\u00fcme beklentilerine kadar her \u015feyi detayl\u0131ca inceleyelim."},"body_html":"<h2>\ud83d\udcc8 G\u00fcncel Piyasa Konumu ve Anl\u0131k F\u0131rsatlar<\/h2> <p><strong>26 A\u011fustos 2025 itibar\u0131yla, Nurix Therapeutics (NRIX) hisseleri hisse ba\u015f\u0131na 9,84 $ seviyesinde i\u015flem g\u00f6r\u00fcyor<\/strong>\u2014biyoteknoloji sekt\u00f6r\u00fcne giri\u015f yapmak isteyen yat\u0131r\u0131mc\u0131lar i\u00e7in kritik bir d\u00f6neme\u00e7. Bu fiyat seviyesi, analistlerin ortak hedeflerinin olduk\u00e7a alt\u0131nda bulunuyor ve bir\u00e7ok ki\u015fi taraf\u0131ndan cazip bir al\u0131m f\u0131rsat\u0131 olarak de\u011ferlendiriliyor.<\/p> <p><strong>Takviminize not edin: 10 Ekim 2025 patlay\u0131c\u0131 olabilir.<\/strong> Bu tarihte Nurix, 3. \u00e7eyrek kazan\u00e7lar\u0131n\u0131 a\u00e7\u0131klayacak ve ge\u00e7mi\u015fteki \u00f6r\u00fcnt\u00fcler \u00f6nemli fiyat hareketleri olaca\u011f\u0131n\u0131 g\u00f6steriyor. \u00d6nceki 2. \u00e7eyrek raporu 9 Temmuz 2025'te beklentilerin \u00e7ok \u00fczerinde gelir a\u00e7\u0131klad\u0131\u201444,1 milyon $ ger\u00e7ekle\u015fen gelir, 16,3 milyon $ beklenenin \u00e7ok \u00fcst\u00fcnde\u2014piyasada olumlu \u015fok dalgalar\u0131 yaratt\u0131.<\/p> <h3>Kazan\u00e7lar\u0131n Etki Analizi: Son Tarih\u00e7eden Dersler<\/h3> <p>Nurix, beklentileri a\u015fma e\u011filimi g\u00f6sterdi; \u00f6nceki 12 kazan\u00e7 raporunun 8'inde hisse fiyatlar\u0131 y\u00fckseldi. Ortalama hisse hareketi? A\u00e7\u0131klamay\u0131 takip eden ilk i\u015flem g\u00fcn\u00fcnde %1,8 art\u0131\u015f. En son 2. \u00e7eyrek raporu bu \u00f6r\u00fcnt\u00fcy\u00fc m\u00fckemmel \u015fekilde g\u00f6sterdi ve \u015firketin piyasalar\u0131 olumlu \u015fekilde \u015fa\u015f\u0131rtma yetene\u011fini ortaya koydu.<\/p> <p><strong>Son Kazan\u00e7 Performans\u0131 \u00d6zeti:<\/strong><\/p> <ul> <li>2. \u00c7eyrek 2025: Gelir beklentiyi %170 a\u015ft\u0131 (44,1M $ ger\u00e7ekle\u015fen vs 16,3M $ beklenen)<\/li> <li>1. \u00c7eyrek 2025: 18,5M $ gelir vs 13M $ tahmin (y\u00fczde 42 a\u015f\u0131m)<\/li> <li>Negatif olmas\u0131na ra\u011fmen tutarl\u0131 EPS iyile\u015fmeleri (zararlar\u0131n daralmas\u0131)<\/li> <\/ul> [cta_green text=\"Ticarete Ba\u015fla\"]<h2>\ud83d\udd0d 6 Ayl\u0131k Fiyat Yolculu\u011fu: Biyoteknoloji Dalgalanmas\u0131nda S\u00fcr\u00fc\u015f<\/h2> <p>Son alt\u0131 ayda, NRIX klasik biyoteknoloji volatilitesini ya\u015fad\u0131; bu volatilite sab\u0131rs\u0131z yat\u0131r\u0131mc\u0131lar\u0131 sab\u0131rl\u0131 olanlardan ay\u0131r\u0131yor:<\/p> <ul> <li><strong>\u015eubat-Mart 2025:<\/strong> \u015eirket \u00f6nemli klinik veri a\u00e7\u0131klamalar\u0131na haz\u0131rlan\u0131rken hisse 11-12 $ aral\u0131\u011f\u0131nda istikrar buldu<\/li> <li><strong>Nisan 2025:<\/strong> Daha geni\u015f biyoteknoloji sekt\u00f6r\u00fcndeki dalgalanma nedeniyle ge\u00e7ici %5,9 d\u00fc\u015f\u00fc\u015f ya\u015fand\u0131\u2014\u015firketin temel performans\u0131yla ilgisi yoktu<\/li> <li><strong>May\u0131s-Haziran 2025:<\/strong> Sanofi ile ortakl\u0131k haberleriyle 15M $ lisans \u00fccreti geliri sa\u011flanarak kademeli toparlanma<\/li> <li><strong>Temmuz 2025:<\/strong> 2. \u00e7eyrek kazan\u00e7 patlamas\u0131 yat\u0131r\u0131mc\u0131 heyecan\u0131n\u0131 yeniledi<\/li> <li><strong>A\u011fustos 2025:<\/strong> Piyasalar bir sonraki kataliz\u00f6r\u00fc beklerken 9,84 $ civar\u0131nda konsolidasyon<\/li> <\/ul> <p>Genel e\u011filim? K\u0131sa vadeli dalgalanmalara ra\u011fmen temel hikaye her \u00e7eyrek raporla g\u00fc\u00e7lenmeye devam ediyor.<\/p> <h2>\ud83d\udd2e Fiyat Tahmini: 2025-2030 B\u00fcy\u00fcme Yolu<\/h2> <p><strong>2025 Y\u0131l Sonu Hedefi: 26-32 $<\/strong> (y\u00fczde 165-225 y\u00fckseli\u015f)<br\/> Mevcut analist ortalamas\u0131 29,13 $ hedef ve yakla\u015fan 3. \u00e7eyrek kazan\u00e7 kataliz\u00f6r\u00fc baz al\u0131narak<\/p> <p><strong>2026 Projeksiyonu: 35-45 $<\/strong><br\/> Klinik denemeler ilerledik\u00e7e ve ortakl\u0131k gelirleri h\u0131zland\u0131k\u00e7a<\/p> <p><strong>2028 G\u00f6r\u00fcn\u00fcm\u00fc: 55-70 $<\/strong><br\/> \u00d6nc\u00fc varl\u0131klar\u0131n potansiyel ticarile\u015fmesi ve pazar penetrasyonunun geni\u015flemesi<\/p> <p><strong>2030 Vizyonu: 80-100+ $<\/strong><br\/> Tam ticari lansman ve b\u00fcy\u00fck ila\u00e7 \u015firketlerinden olas\u0131 sat\u0131n alma ilgisi<\/p> <p><strong>Karar: G\u00dc\u00c7L\u00dc AL<\/strong> \u2014 Risk-getiri oran\u0131 mevcut seviyelerde agresif birikimi destekliyor<\/p> <h2>\u26a0\ufe0f Riskleri Anlamak: Biyoteknoloji Ger\u00e7ekleri<\/h2> <p>Y\u00fckseli\u015f potansiyeli \u00e7ok b\u00fcy\u00fck olsa da, biyoteknoloji yat\u0131r\u0131m\u0131 benzersiz riskler ta\u015f\u0131r:<\/p> <ul> <li><strong>Klinik Deneme Riski:<\/strong> Tek bir ba\u015far\u0131s\u0131z deneme de\u011ferin %50-80'ini bir gecede silebilir<\/li> <li><strong>Reg\u00fclasyon Belirsizli\u011fi:<\/strong> FDA onaylar\u0131 pozitif verilere ra\u011fmen asla garanti de\u011fildir<\/li> <li><strong>Nakit T\u00fcketimi Endi\u015fesi:<\/strong> 485,8M $ nakit pozisyonuna ra\u011fmen \u015firket y\u0131lda yakla\u015f\u0131k 125M $ harc\u0131yor<\/li> <li><strong>Sekt\u00f6r Volatilitesi:<\/strong> Biyoteknoloji hisseleri \u015firket performans\u0131ndan \u00e7ok sekt\u00f6r duyarl\u0131l\u0131\u011f\u0131na ba\u011fl\u0131 hareket eder<\/li> <li><strong>Ortakl\u0131k Ba\u011f\u0131ml\u0131l\u0131\u011f\u0131:<\/strong> Gelirler b\u00fcy\u00fck \u00f6l\u00e7\u00fcde Sanofi\/Pfizer anla\u015fmalar\u0131ndan gelen kilometre ta\u015f\u0131 \u00f6demelerine dayan\u0131yor<\/li> <\/ul> <h2>\ud83d\udea6 Ye\u015fil I\u015f\u0131klar: 2025 Neden \u00dcmit Vaat Ediyor<\/h2> <ul> <li><strong>Klinik Ba\u015far\u0131:<\/strong> Tedaviye diren\u00e7li CLL hastalar\u0131nda %80,9 yan\u0131t oran\u0131 ola\u011fan\u00fcst\u00fc<\/li> <li><strong>Mali G\u00fc\u00e7:<\/strong> 485,8M $ nakit 2027'ye kadar finansal destek sa\u011fl\u0131yor\u2014geli\u015fim i\u00e7in yeterli zaman<\/li> <li><strong>Analist Deste\u011fi:<\/strong> 16 \"Al\" derecelendirmesi ve sadece 2 \"Tut\" \u2014 biyoteknolojide nadir bir fikir birli\u011fi<\/li> <li><strong>Teknoloji Platformu:<\/strong> Protein y\u0131k\u0131m\u0131, yeni nesil tedavi y\u00f6ntemi olarak \u00f6ne \u00e7\u0131k\u0131yor<\/li> <li><strong>Ortakl\u0131k Momentum:<\/strong> Sanofi uzatmas\u0131ndan 15M $ lisans \u00fccreti do\u011frulama sa\u011fl\u0131yor<\/li> <\/ul> <h2>\ud83c\udfaf Yeni Ba\u015flayan Bir T\u00fcccar Bug\u00fcn Ne Yapmal\u0131?<\/h2> <ol> <li><strong>K\u00fc\u00e7\u00fck Ba\u015flay\u0131n:<\/strong> Portf\u00f6y\u00fcn\u00fcz\u00fcn %5'inden fazlas\u0131n\u0131 y\u00fcksek riskli biyoteknoloji hisselerine ay\u0131rmay\u0131n<\/li> <li><strong>Dolar Maliyet Ortalamas\u0131:<\/strong> Tek seferde b\u00fcy\u00fck pozisyon yerine haftal\u0131k al\u0131mlar yap\u0131n<\/li> <li><strong>Fiyat Uyar\u0131lar\u0131 Kurun:<\/strong> 9,50 $ alt\u0131na d\u00fc\u015f\u00fc\u015flerde ek al\u0131m i\u00e7in takipte olun<\/li> <li><strong>10 Ekim'i \u0130zleyin:<\/strong> Tez sa\u011flam kal\u0131rsa 3. \u00e7eyrek kazan\u00e7 \u00f6ncesi ekleme planlay\u0131n<\/li> <li><strong>Esprili Ger\u00e7eklik Kontrol\u00fc:<\/strong> \"Biyoteknoloji hisseleriyle ticaret yapmak, dahi bir bilim insan\u0131yla \u00e7\u0131kmak gibidir\u2014heyecan verici at\u0131l\u0131mlar ve ara s\u0131ra laboratuvar patlamalar\u0131. Koruyucu g\u00f6zl\u00fcklerinizi takmay\u0131 unutmay\u0131n!\"<\/li> <\/ol> <h2>\u2705 Nurix Therapeutics, Inc. (NRIX) Hisseleri Nas\u0131l Al\u0131n\u0131r - Ad\u0131m Ad\u0131m<\/h2> <table> <thead> <tr><th>Ad\u0131m<\/th><th>\u0130\u015flem<\/th><th>Neden \u00d6nemli<\/th><\/tr> <\/thead> <tbody> <tr><td>1<\/td><td>Bir ticaret platformu se\u00e7in<\/td><td>NASDAQ listeleri ve biyoteknoloji hisseleri sunmas\u0131na dikkat edin<\/td><\/tr> <tr><td>2<\/td><td>Hesap fonlamas\u0131n\u0131 tamamlay\u0131n<\/td><td>Y\u00f6netilebilir bir miktarla ba\u015flay\u0131n\u2014100 $ bile yeterli<\/td><\/tr> <tr><td>3<\/td><td>\"NRIX\" aramas\u0131 yap\u0131n<\/td><td>Do\u011fru fiyatland\u0131rma i\u00e7in tam sembol\u00fc kullan\u0131n<\/td><\/tr> <tr><td>4<\/td><td>Emir t\u00fcr\u00fcn\u00fc se\u00e7in<\/td><td>Giri\u015f fiyat\u0131n\u0131 kontrol etmek i\u00e7in limit emirleri kullan\u0131n (9,70-10,00 $ \u00f6nerilir)<\/td><\/tr> <tr><td>5<\/td><td>\u0130nceleyin ve onaylay\u0131n<\/td><td>Komisyon oranlar\u0131n\u0131 kontrol edin\u2014%1'in alt\u0131nda i\u015flem maliyeti hedefleyin<\/td><\/tr> <tr><td>6<\/td><td>Fiyat uyar\u0131lar\u0131 kurun<\/td><td>Kazan\u00e7 tarihleri civar\u0131nda f\u0131rsatlar\u0131 takip edin<\/td><\/tr> <tr><td>7<\/td><td>K\u00e2r hedefleri belirleyin<\/td><td>Analist hedeflerine g\u00f6re 28-32 $ aral\u0131\u011f\u0131nda \u00e7\u0131k\u0131\u015f stratejisi planlay\u0131n<\/td><\/tr> <tr><td>8<\/td><td>Zarar durdurma uygulay\u0131n<\/td><td>Volatilite g\u00f6z \u00f6n\u00fcnde bulundurularak %20-25 a\u015fa\u011f\u0131 koruma d\u00fc\u015f\u00fcn\u00fcn<\/td><\/tr> <tr><td>9<\/td><td>Tezinizi belgeleyin<\/td><td>Duygusal sat\u0131\u015flardan ka\u00e7\u0131nmak i\u00e7in neden ald\u0131\u011f\u0131n\u0131z\u0131 yaz\u0131n<\/td><\/tr> <tr><td>10<\/td><td>\u00c7eyrek d\u00f6nemlerde g\u00f6zden ge\u00e7irin<\/td><td>Her kazan\u00e7 raporu ve klinik g\u00fcncellemeden sonra yeniden de\u011ferlendirin<\/td><\/tr> <\/tbody> <\/table> <h2>\ud83d\udca1 Pocket Option Yeni Biyoteknoloji Yat\u0131r\u0131mc\u0131lar\u0131na Neden Cazip?<\/h2> <p>Dalgal\u0131 biyoteknoloji hisselerinde deneme yapanlar i\u00e7in Pocket Option benzersiz avantajlar sunar:<\/p> <ul> <li><strong>Sadece 5 $ minimum depozito<\/strong> k\u00fc\u00e7\u00fck pozisyonlarla risksiz deneme imkan\u0131 sa\u011flar<\/li> <li><strong>H\u0131zl\u0131 do\u011frulama s\u00fcreci<\/strong> karar verdikten dakikalar i\u00e7inde i\u015flem yapmaya ba\u015flayabilirsiniz<\/li> <li><strong>\u00c7oklu para \u00e7ekme se\u00e7enekleri<\/strong> ba\u015far\u0131l\u0131 i\u015flemlerden kar al\u0131rken esneklik sunar<\/li> <li><strong>Ger\u00e7ek zamanl\u0131 piyasa verisi<\/strong> h\u0131zl\u0131 hareket eden biyoteknoloji sekt\u00f6r\u00fcnde g\u00fcncel fiyatlarla \u00e7al\u0131\u015fman\u0131z\u0131 sa\u011flar<\/li> <\/ul> <h2>\ud83c\udf0d 2025'te Nurix Therapeutics: Protein Y\u0131k\u0131m\u0131 \u00d6nc\u00fcs\u00fc<\/h2> <p>Nurix Therapeutics, biyoteknolojinin en heyecan verici alanlar\u0131ndan biri olan hedefe y\u00f6nelik protein y\u0131k\u0131m\u0131nda \u00f6nc\u00fc konumdad\u0131r. \u015eirketin DELigase platformu, v\u00fccudun do\u011fal protein d\u00fczenleme sistemini kullanarak kanser ve inflamatuar hastal\u0131klar\u0131 tedavi etmeye odaklanan devrim niteli\u011finde bir ila\u00e7 ke\u015fif yakla\u015f\u0131m\u0131n\u0131 temsil eder.<\/p> <p>\u015eu anda yakla\u015f\u0131k 775 milyon $ piyasa de\u011feriyle i\u015flem g\u00f6ren Nurix, Sanofi ve Pfizer gibi sekt\u00f6r devleriyle i\u015f birlikleri s\u00fcrd\u00fcrerek teknolojik yakla\u015f\u0131m\u0131n\u0131 do\u011frulamaktad\u0131r. \u015eirketin \u00f6nc\u00fc varl\u0131\u011f\u0131 olan bexobrutinib y\u0131k\u0131c\u0131 (NX-5948), tedaviye diren\u00e7li kanser hastalar\u0131nda %80,9 yan\u0131t oran\u0131 g\u00f6stermi\u015ftir.<\/p> <p><strong>2025 \u0130lgin\u00e7 Ger\u00e7ek:<\/strong> Nurix'in yapay zeka destekli ila\u00e7 ke\u015fif platformu DEL-AI, onlarca y\u0131ll\u0131k ara\u015ft\u0131rma verisini saatler i\u00e7inde analiz edebiliyor\u2014dijital h\u0131zda \u00e7al\u0131\u015fan bir Nobel \u00f6d\u00fcll\u00fc kimyageriniz oldu\u011funu hayal edin! Bu teknoloji yak\u0131n zamanda geleneksel y\u00f6ntemlerin y\u0131llar alaca\u011f\u0131 \u00fc\u00e7 yeni ila\u00e7 aday\u0131n\u0131 belirledi.<\/p>","body_html_source":{"label":"Body HTML","type":"wysiwyg","formatted_value":"<h2>\ud83d\udcc8 G\u00fcncel Piyasa Konumu ve Anl\u0131k F\u0131rsatlar<\/h2>\n<p><strong>26 A\u011fustos 2025 itibar\u0131yla, Nurix Therapeutics (NRIX) hisseleri hisse ba\u015f\u0131na 9,84 $ seviyesinde i\u015flem g\u00f6r\u00fcyor<\/strong>\u2014biyoteknoloji sekt\u00f6r\u00fcne giri\u015f yapmak isteyen yat\u0131r\u0131mc\u0131lar i\u00e7in kritik bir d\u00f6neme\u00e7. Bu fiyat seviyesi, analistlerin ortak hedeflerinin olduk\u00e7a alt\u0131nda bulunuyor ve bir\u00e7ok ki\u015fi taraf\u0131ndan cazip bir al\u0131m f\u0131rsat\u0131 olarak de\u011ferlendiriliyor.<\/p>\n<p><strong>Takviminize not edin: 10 Ekim 2025 patlay\u0131c\u0131 olabilir.<\/strong> Bu tarihte Nurix, 3. \u00e7eyrek kazan\u00e7lar\u0131n\u0131 a\u00e7\u0131klayacak ve ge\u00e7mi\u015fteki \u00f6r\u00fcnt\u00fcler \u00f6nemli fiyat hareketleri olaca\u011f\u0131n\u0131 g\u00f6steriyor. \u00d6nceki 2. \u00e7eyrek raporu 9 Temmuz 2025&#8217;te beklentilerin \u00e7ok \u00fczerinde gelir a\u00e7\u0131klad\u0131\u201444,1 milyon $ ger\u00e7ekle\u015fen gelir, 16,3 milyon $ beklenenin \u00e7ok \u00fcst\u00fcnde\u2014piyasada olumlu \u015fok dalgalar\u0131 yaratt\u0131.<\/p>\n<h3>Kazan\u00e7lar\u0131n Etki Analizi: Son Tarih\u00e7eden Dersler<\/h3>\n<p>Nurix, beklentileri a\u015fma e\u011filimi g\u00f6sterdi; \u00f6nceki 12 kazan\u00e7 raporunun 8&#8217;inde hisse fiyatlar\u0131 y\u00fckseldi. Ortalama hisse hareketi? A\u00e7\u0131klamay\u0131 takip eden ilk i\u015flem g\u00fcn\u00fcnde %1,8 art\u0131\u015f. En son 2. \u00e7eyrek raporu bu \u00f6r\u00fcnt\u00fcy\u00fc m\u00fckemmel \u015fekilde g\u00f6sterdi ve \u015firketin piyasalar\u0131 olumlu \u015fekilde \u015fa\u015f\u0131rtma yetene\u011fini ortaya koydu.<\/p>\n<p><strong>Son Kazan\u00e7 Performans\u0131 \u00d6zeti:<\/strong><\/p>\n<ul>\n<li>2. \u00c7eyrek 2025: Gelir beklentiyi %170 a\u015ft\u0131 (44,1M $ ger\u00e7ekle\u015fen vs 16,3M $ beklenen)<\/li>\n<li>1. \u00c7eyrek 2025: 18,5M $ gelir vs 13M $ tahmin (y\u00fczde 42 a\u015f\u0131m)<\/li>\n<li>Negatif olmas\u0131na ra\u011fmen tutarl\u0131 EPS iyile\u015fmeleri (zararlar\u0131n daralmas\u0131)<\/li>\n<\/ul>\n<div class=\"po-container po-container_width_article\">\n   <div class=\"po-cta-green__wrap\">\n      <a href=\"https:\/\/pocketoption.com\/tr\/register\/\" class=\"po-cta-green\">Ticarete Ba\u015fla\n         <span class=\"po-cta-green__icon\">\n            <svg width=\"24\" height=\"24\" fill=\"none\" aria-hidden=\"true\">\n               <use href=\"#svg-arrow-cta\"><\/use>\n            <\/svg>\n         <\/span>\n      <\/a>\n   <\/div>\n<\/div>\n<h2>\ud83d\udd0d 6 Ayl\u0131k Fiyat Yolculu\u011fu: Biyoteknoloji Dalgalanmas\u0131nda S\u00fcr\u00fc\u015f<\/h2>\n<p>Son alt\u0131 ayda, NRIX klasik biyoteknoloji volatilitesini ya\u015fad\u0131; bu volatilite sab\u0131rs\u0131z yat\u0131r\u0131mc\u0131lar\u0131 sab\u0131rl\u0131 olanlardan ay\u0131r\u0131yor:<\/p>\n<ul>\n<li><strong>\u015eubat-Mart 2025:<\/strong> \u015eirket \u00f6nemli klinik veri a\u00e7\u0131klamalar\u0131na haz\u0131rlan\u0131rken hisse 11-12 $ aral\u0131\u011f\u0131nda istikrar buldu<\/li>\n<li><strong>Nisan 2025:<\/strong> Daha geni\u015f biyoteknoloji sekt\u00f6r\u00fcndeki dalgalanma nedeniyle ge\u00e7ici %5,9 d\u00fc\u015f\u00fc\u015f ya\u015fand\u0131\u2014\u015firketin temel performans\u0131yla ilgisi yoktu<\/li>\n<li><strong>May\u0131s-Haziran 2025:<\/strong> Sanofi ile ortakl\u0131k haberleriyle 15M $ lisans \u00fccreti geliri sa\u011flanarak kademeli toparlanma<\/li>\n<li><strong>Temmuz 2025:<\/strong> 2. \u00e7eyrek kazan\u00e7 patlamas\u0131 yat\u0131r\u0131mc\u0131 heyecan\u0131n\u0131 yeniledi<\/li>\n<li><strong>A\u011fustos 2025:<\/strong> Piyasalar bir sonraki kataliz\u00f6r\u00fc beklerken 9,84 $ civar\u0131nda konsolidasyon<\/li>\n<\/ul>\n<p>Genel e\u011filim? K\u0131sa vadeli dalgalanmalara ra\u011fmen temel hikaye her \u00e7eyrek raporla g\u00fc\u00e7lenmeye devam ediyor.<\/p>\n<h2>\ud83d\udd2e Fiyat Tahmini: 2025-2030 B\u00fcy\u00fcme Yolu<\/h2>\n<p><strong>2025 Y\u0131l Sonu Hedefi: 26-32 $<\/strong> (y\u00fczde 165-225 y\u00fckseli\u015f)<br \/> Mevcut analist ortalamas\u0131 29,13 $ hedef ve yakla\u015fan 3. \u00e7eyrek kazan\u00e7 kataliz\u00f6r\u00fc baz al\u0131narak<\/p>\n<p><strong>2026 Projeksiyonu: 35-45 $<\/strong><br \/> Klinik denemeler ilerledik\u00e7e ve ortakl\u0131k gelirleri h\u0131zland\u0131k\u00e7a<\/p>\n<p><strong>2028 G\u00f6r\u00fcn\u00fcm\u00fc: 55-70 $<\/strong><br \/> \u00d6nc\u00fc varl\u0131klar\u0131n potansiyel ticarile\u015fmesi ve pazar penetrasyonunun geni\u015flemesi<\/p>\n<p><strong>2030 Vizyonu: 80-100+ $<\/strong><br \/> Tam ticari lansman ve b\u00fcy\u00fck ila\u00e7 \u015firketlerinden olas\u0131 sat\u0131n alma ilgisi<\/p>\n<p><strong>Karar: G\u00dc\u00c7L\u00dc AL<\/strong> \u2014 Risk-getiri oran\u0131 mevcut seviyelerde agresif birikimi destekliyor<\/p>\n<h2>\u26a0\ufe0f Riskleri Anlamak: Biyoteknoloji Ger\u00e7ekleri<\/h2>\n<p>Y\u00fckseli\u015f potansiyeli \u00e7ok b\u00fcy\u00fck olsa da, biyoteknoloji yat\u0131r\u0131m\u0131 benzersiz riskler ta\u015f\u0131r:<\/p>\n<ul>\n<li><strong>Klinik Deneme Riski:<\/strong> Tek bir ba\u015far\u0131s\u0131z deneme de\u011ferin %50-80&#8217;ini bir gecede silebilir<\/li>\n<li><strong>Reg\u00fclasyon Belirsizli\u011fi:<\/strong> FDA onaylar\u0131 pozitif verilere ra\u011fmen asla garanti de\u011fildir<\/li>\n<li><strong>Nakit T\u00fcketimi Endi\u015fesi:<\/strong> 485,8M $ nakit pozisyonuna ra\u011fmen \u015firket y\u0131lda yakla\u015f\u0131k 125M $ harc\u0131yor<\/li>\n<li><strong>Sekt\u00f6r Volatilitesi:<\/strong> Biyoteknoloji hisseleri \u015firket performans\u0131ndan \u00e7ok sekt\u00f6r duyarl\u0131l\u0131\u011f\u0131na ba\u011fl\u0131 hareket eder<\/li>\n<li><strong>Ortakl\u0131k Ba\u011f\u0131ml\u0131l\u0131\u011f\u0131:<\/strong> Gelirler b\u00fcy\u00fck \u00f6l\u00e7\u00fcde Sanofi\/Pfizer anla\u015fmalar\u0131ndan gelen kilometre ta\u015f\u0131 \u00f6demelerine dayan\u0131yor<\/li>\n<\/ul>\n<h2>\ud83d\udea6 Ye\u015fil I\u015f\u0131klar: 2025 Neden \u00dcmit Vaat Ediyor<\/h2>\n<ul>\n<li><strong>Klinik Ba\u015far\u0131:<\/strong> Tedaviye diren\u00e7li CLL hastalar\u0131nda %80,9 yan\u0131t oran\u0131 ola\u011fan\u00fcst\u00fc<\/li>\n<li><strong>Mali G\u00fc\u00e7:<\/strong> 485,8M $ nakit 2027&#8217;ye kadar finansal destek sa\u011fl\u0131yor\u2014geli\u015fim i\u00e7in yeterli zaman<\/li>\n<li><strong>Analist Deste\u011fi:<\/strong> 16 &#8220;Al&#8221; derecelendirmesi ve sadece 2 &#8220;Tut&#8221; \u2014 biyoteknolojide nadir bir fikir birli\u011fi<\/li>\n<li><strong>Teknoloji Platformu:<\/strong> Protein y\u0131k\u0131m\u0131, yeni nesil tedavi y\u00f6ntemi olarak \u00f6ne \u00e7\u0131k\u0131yor<\/li>\n<li><strong>Ortakl\u0131k Momentum:<\/strong> Sanofi uzatmas\u0131ndan 15M $ lisans \u00fccreti do\u011frulama sa\u011fl\u0131yor<\/li>\n<\/ul>\n<h2>\ud83c\udfaf Yeni Ba\u015flayan Bir T\u00fcccar Bug\u00fcn Ne Yapmal\u0131?<\/h2>\n<ol>\n<li><strong>K\u00fc\u00e7\u00fck Ba\u015flay\u0131n:<\/strong> Portf\u00f6y\u00fcn\u00fcz\u00fcn %5&#8217;inden fazlas\u0131n\u0131 y\u00fcksek riskli biyoteknoloji hisselerine ay\u0131rmay\u0131n<\/li>\n<li><strong>Dolar Maliyet Ortalamas\u0131:<\/strong> Tek seferde b\u00fcy\u00fck pozisyon yerine haftal\u0131k al\u0131mlar yap\u0131n<\/li>\n<li><strong>Fiyat Uyar\u0131lar\u0131 Kurun:<\/strong> 9,50 $ alt\u0131na d\u00fc\u015f\u00fc\u015flerde ek al\u0131m i\u00e7in takipte olun<\/li>\n<li><strong>10 Ekim&#8217;i \u0130zleyin:<\/strong> Tez sa\u011flam kal\u0131rsa 3. \u00e7eyrek kazan\u00e7 \u00f6ncesi ekleme planlay\u0131n<\/li>\n<li><strong>Esprili Ger\u00e7eklik Kontrol\u00fc:<\/strong> &#8220;Biyoteknoloji hisseleriyle ticaret yapmak, dahi bir bilim insan\u0131yla \u00e7\u0131kmak gibidir\u2014heyecan verici at\u0131l\u0131mlar ve ara s\u0131ra laboratuvar patlamalar\u0131. Koruyucu g\u00f6zl\u00fcklerinizi takmay\u0131 unutmay\u0131n!&#8221;<\/li>\n<\/ol>\n<h2>\u2705 Nurix Therapeutics, Inc. (NRIX) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Ad\u0131m Ad\u0131m<\/h2>\n<table>\n<thead>\n<tr>\n<th>Ad\u0131m<\/th>\n<th>\u0130\u015flem<\/th>\n<th>Neden \u00d6nemli<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>1<\/td>\n<td>Bir ticaret platformu se\u00e7in<\/td>\n<td>NASDAQ listeleri ve biyoteknoloji hisseleri sunmas\u0131na dikkat edin<\/td>\n<\/tr>\n<tr>\n<td>2<\/td>\n<td>Hesap fonlamas\u0131n\u0131 tamamlay\u0131n<\/td>\n<td>Y\u00f6netilebilir bir miktarla ba\u015flay\u0131n\u2014100 $ bile yeterli<\/td>\n<\/tr>\n<tr>\n<td>3<\/td>\n<td>&#8220;NRIX&#8221; aramas\u0131 yap\u0131n<\/td>\n<td>Do\u011fru fiyatland\u0131rma i\u00e7in tam sembol\u00fc kullan\u0131n<\/td>\n<\/tr>\n<tr>\n<td>4<\/td>\n<td>Emir t\u00fcr\u00fcn\u00fc se\u00e7in<\/td>\n<td>Giri\u015f fiyat\u0131n\u0131 kontrol etmek i\u00e7in limit emirleri kullan\u0131n (9,70-10,00 $ \u00f6nerilir)<\/td>\n<\/tr>\n<tr>\n<td>5<\/td>\n<td>\u0130nceleyin ve onaylay\u0131n<\/td>\n<td>Komisyon oranlar\u0131n\u0131 kontrol edin\u2014%1&#8217;in alt\u0131nda i\u015flem maliyeti hedefleyin<\/td>\n<\/tr>\n<tr>\n<td>6<\/td>\n<td>Fiyat uyar\u0131lar\u0131 kurun<\/td>\n<td>Kazan\u00e7 tarihleri civar\u0131nda f\u0131rsatlar\u0131 takip edin<\/td>\n<\/tr>\n<tr>\n<td>7<\/td>\n<td>K\u00e2r hedefleri belirleyin<\/td>\n<td>Analist hedeflerine g\u00f6re 28-32 $ aral\u0131\u011f\u0131nda \u00e7\u0131k\u0131\u015f stratejisi planlay\u0131n<\/td>\n<\/tr>\n<tr>\n<td>8<\/td>\n<td>Zarar durdurma uygulay\u0131n<\/td>\n<td>Volatilite g\u00f6z \u00f6n\u00fcnde bulundurularak %20-25 a\u015fa\u011f\u0131 koruma d\u00fc\u015f\u00fcn\u00fcn<\/td>\n<\/tr>\n<tr>\n<td>9<\/td>\n<td>Tezinizi belgeleyin<\/td>\n<td>Duygusal sat\u0131\u015flardan ka\u00e7\u0131nmak i\u00e7in neden ald\u0131\u011f\u0131n\u0131z\u0131 yaz\u0131n<\/td>\n<\/tr>\n<tr>\n<td>10<\/td>\n<td>\u00c7eyrek d\u00f6nemlerde g\u00f6zden ge\u00e7irin<\/td>\n<td>Her kazan\u00e7 raporu ve klinik g\u00fcncellemeden sonra yeniden de\u011ferlendirin<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2>\ud83d\udca1 Pocket Option Yeni Biyoteknoloji Yat\u0131r\u0131mc\u0131lar\u0131na Neden Cazip?<\/h2>\n<p>Dalgal\u0131 biyoteknoloji hisselerinde deneme yapanlar i\u00e7in Pocket Option benzersiz avantajlar sunar:<\/p>\n<ul>\n<li><strong>Sadece 5 $ minimum depozito<\/strong> k\u00fc\u00e7\u00fck pozisyonlarla risksiz deneme imkan\u0131 sa\u011flar<\/li>\n<li><strong>H\u0131zl\u0131 do\u011frulama s\u00fcreci<\/strong> karar verdikten dakikalar i\u00e7inde i\u015flem yapmaya ba\u015flayabilirsiniz<\/li>\n<li><strong>\u00c7oklu para \u00e7ekme se\u00e7enekleri<\/strong> ba\u015far\u0131l\u0131 i\u015flemlerden kar al\u0131rken esneklik sunar<\/li>\n<li><strong>Ger\u00e7ek zamanl\u0131 piyasa verisi<\/strong> h\u0131zl\u0131 hareket eden biyoteknoloji sekt\u00f6r\u00fcnde g\u00fcncel fiyatlarla \u00e7al\u0131\u015fman\u0131z\u0131 sa\u011flar<\/li>\n<\/ul>\n<h2>\ud83c\udf0d 2025&#8217;te Nurix Therapeutics: Protein Y\u0131k\u0131m\u0131 \u00d6nc\u00fcs\u00fc<\/h2>\n<p>Nurix Therapeutics, biyoteknolojinin en heyecan verici alanlar\u0131ndan biri olan hedefe y\u00f6nelik protein y\u0131k\u0131m\u0131nda \u00f6nc\u00fc konumdad\u0131r. \u015eirketin DELigase platformu, v\u00fccudun do\u011fal protein d\u00fczenleme sistemini kullanarak kanser ve inflamatuar hastal\u0131klar\u0131 tedavi etmeye odaklanan devrim niteli\u011finde bir ila\u00e7 ke\u015fif yakla\u015f\u0131m\u0131n\u0131 temsil eder.<\/p>\n<p>\u015eu anda yakla\u015f\u0131k 775 milyon $ piyasa de\u011feriyle i\u015flem g\u00f6ren Nurix, Sanofi ve Pfizer gibi sekt\u00f6r devleriyle i\u015f birlikleri s\u00fcrd\u00fcrerek teknolojik yakla\u015f\u0131m\u0131n\u0131 do\u011frulamaktad\u0131r. \u015eirketin \u00f6nc\u00fc varl\u0131\u011f\u0131 olan bexobrutinib y\u0131k\u0131c\u0131 (NX-5948), tedaviye diren\u00e7li kanser hastalar\u0131nda %80,9 yan\u0131t oran\u0131 g\u00f6stermi\u015ftir.<\/p>\n<p><strong>2025 \u0130lgin\u00e7 Ger\u00e7ek:<\/strong> Nurix&#8217;in yapay zeka destekli ila\u00e7 ke\u015fif platformu DEL-AI, onlarca y\u0131ll\u0131k ara\u015ft\u0131rma verisini saatler i\u00e7inde analiz edebiliyor\u2014dijital h\u0131zda \u00e7al\u0131\u015fan bir Nobel \u00f6d\u00fcll\u00fc kimyageriniz oldu\u011funu hayal edin! Bu teknoloji yak\u0131n zamanda geleneksel y\u00f6ntemlerin y\u0131llar alaca\u011f\u0131 \u00fc\u00e7 yeni ila\u00e7 aday\u0131n\u0131 belirledi.<\/p>\n"},"faq":[{"question":"Nurix Therapeutics hisseleri nereden al\u0131nabilir?","answer":"Nurix Therapeutics hisseleri NASDAQ borsas\u0131nda i\u015flem g\u00f6rmektedir. G\u00fcvenilir bir arac\u0131 kurum veya online ticaret platformu \u00fczerinden NRIX sembol\u00fc ile al\u0131m yapabilirsiniz."},{"question":"Nurix Therapeutics hisseleri i\u00e7in 2025 sonu fiyat hedefi nedir?","answer":"Analistlerin ortalama hedefi 26-32 $ aral\u0131\u011f\u0131nda olup, bu %165-225 aras\u0131nda bir y\u00fckseli\u015f potansiyeline i\u015faret etmektedir."},{"question":"Nurix Therapeutics yat\u0131r\u0131m\u0131nda hangi riskler vard\u0131r?","answer":"Klinik deneme ba\u015far\u0131s\u0131zl\u0131klar\u0131, reg\u00fclasyon belirsizlikleri, y\u00fcksek nakit t\u00fcketimi, sekt\u00f6r volatilitesi ve ortakl\u0131k gelirlerine ba\u011f\u0131ml\u0131l\u0131k ba\u015fl\u0131ca risklerdir."},{"question":"Yeni ba\u015flayanlar Nurix hisselerini nas\u0131l almal\u0131?","answer":"Portf\u00f6y\u00fcn\u00fcz\u00fcn %5'inden fazlas\u0131n\u0131 ay\u0131rmadan k\u00fc\u00e7\u00fck ba\u015flay\u0131n, dolar maliyet ortalamas\u0131 yap\u0131n, fiyat uyar\u0131lar\u0131 kurun ve \u00f6nemli kazan\u00e7 a\u00e7\u0131klamalar\u0131n\u0131 takip edin."},{"question":"Nurix Therapeutics'in teknolojik avantaj\u0131 nedir?","answer":"Nurix, protein y\u0131k\u0131m\u0131 teknolojisi ile kanser ve inflamatuar hastal\u0131klar\u0131n tedavisinde devrim yaratmay\u0131 hedefleyen DELigase platformuna sahiptir."}],"faq_source":{"label":"FAQ","type":"repeater","formatted_value":[{"question":"Nurix Therapeutics hisseleri nereden al\u0131nabilir?","answer":"Nurix Therapeutics hisseleri NASDAQ borsas\u0131nda i\u015flem g\u00f6rmektedir. G\u00fcvenilir bir arac\u0131 kurum veya online ticaret platformu \u00fczerinden NRIX sembol\u00fc ile al\u0131m yapabilirsiniz."},{"question":"Nurix Therapeutics hisseleri i\u00e7in 2025 sonu fiyat hedefi nedir?","answer":"Analistlerin ortalama hedefi 26-32 $ aral\u0131\u011f\u0131nda olup, bu %165-225 aras\u0131nda bir y\u00fckseli\u015f potansiyeline i\u015faret etmektedir."},{"question":"Nurix Therapeutics yat\u0131r\u0131m\u0131nda hangi riskler vard\u0131r?","answer":"Klinik deneme ba\u015far\u0131s\u0131zl\u0131klar\u0131, reg\u00fclasyon belirsizlikleri, y\u00fcksek nakit t\u00fcketimi, sekt\u00f6r volatilitesi ve ortakl\u0131k gelirlerine ba\u011f\u0131ml\u0131l\u0131k ba\u015fl\u0131ca risklerdir."},{"question":"Yeni ba\u015flayanlar Nurix hisselerini nas\u0131l almal\u0131?","answer":"Portf\u00f6y\u00fcn\u00fcz\u00fcn %5'inden fazlas\u0131n\u0131 ay\u0131rmadan k\u00fc\u00e7\u00fck ba\u015flay\u0131n, dolar maliyet ortalamas\u0131 yap\u0131n, fiyat uyar\u0131lar\u0131 kurun ve \u00f6nemli kazan\u00e7 a\u00e7\u0131klamalar\u0131n\u0131 takip edin."},{"question":"Nurix Therapeutics'in teknolojik avantaj\u0131 nedir?","answer":"Nurix, protein y\u0131k\u0131m\u0131 teknolojisi ile kanser ve inflamatuar hastal\u0131klar\u0131n tedavisinde devrim yaratmay\u0131 hedefleyen DELigase platformuna sahiptir."}]}},"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v24.8 (Yoast SEO v27.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Nurix Therapeutics, Inc. (NRIX) Hisseleri Nas\u0131l Al\u0131n\u0131r - Nurix Therapeutics, Inc. (NRIX) Hisse Senedi Yat\u0131r\u0131m\u0131<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-nurix-therapeutics\/\" \/>\n<meta property=\"og:locale\" content=\"tr_TR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nurix Therapeutics, Inc. (NRIX) Hisseleri Nas\u0131l Al\u0131n\u0131r - Nurix Therapeutics, Inc. (NRIX) Hisse Senedi Yat\u0131r\u0131m\u0131\" \/>\n<meta property=\"og:description\" content=\"text\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-nurix-therapeutics\/\" \/>\n<meta property=\"og:site_name\" content=\"Pocket Option blog\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-26T06:28:30+00:00\" \/>\n<meta name=\"author\" content=\"Signal\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Yazan:\" \/>\n\t<meta name=\"twitter:data1\" content=\"Signal\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-nurix-therapeutics\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-nurix-therapeutics\/\"},\"author\":{\"name\":\"Signal\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"headline\":\"Nurix Therapeutics, Inc. (NRIX) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Nurix Therapeutics, Inc. (NRIX) Hisse Senedi Yat\u0131r\u0131m\u0131\",\"datePublished\":\"2025-08-26T06:28:30+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-nurix-therapeutics\/\"},\"wordCount\":21,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-nurix-therapeutics\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals14-scaled.webp\",\"keywords\":[\"signal\"],\"articleSection\":[\"Signals\"],\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-nurix-therapeutics\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-nurix-therapeutics\/\",\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-nurix-therapeutics\/\",\"name\":\"Nurix Therapeutics, Inc. (NRIX) Hisseleri Nas\u0131l Al\u0131n\u0131r - Nurix Therapeutics, Inc. (NRIX) Hisse Senedi Yat\u0131r\u0131m\u0131\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-nurix-therapeutics\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-nurix-therapeutics\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals14-scaled.webp\",\"datePublished\":\"2025-08-26T06:28:30+00:00\",\"author\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"breadcrumb\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-nurix-therapeutics\/#breadcrumb\"},\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-nurix-therapeutics\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-nurix-therapeutics\/#primaryimage\",\"url\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals14-scaled.webp\",\"contentUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals14-scaled.webp\",\"width\":2560,\"height\":1429},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-nurix-therapeutics\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/pocketoption.com\/blog\/tr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nurix Therapeutics, Inc. (NRIX) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Nurix Therapeutics, Inc. (NRIX) Hisse Senedi Yat\u0131r\u0131m\u0131\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#website\",\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/\",\"name\":\"Pocket Option blog\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/pocketoption.com\/blog\/tr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"tr\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\",\"name\":\"Signal\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"caption\":\"Signal\"},\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/author\/signal\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Nurix Therapeutics, Inc. (NRIX) Hisseleri Nas\u0131l Al\u0131n\u0131r - Nurix Therapeutics, Inc. (NRIX) Hisse Senedi Yat\u0131r\u0131m\u0131","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-nurix-therapeutics\/","og_locale":"tr_TR","og_type":"article","og_title":"Nurix Therapeutics, Inc. (NRIX) Hisseleri Nas\u0131l Al\u0131n\u0131r - Nurix Therapeutics, Inc. (NRIX) Hisse Senedi Yat\u0131r\u0131m\u0131","og_description":"text","og_url":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-nurix-therapeutics\/","og_site_name":"Pocket Option blog","article_published_time":"2025-08-26T06:28:30+00:00","author":"Signal","twitter_card":"summary_large_image","twitter_misc":{"Yazan:":"Signal"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-nurix-therapeutics\/#article","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-nurix-therapeutics\/"},"author":{"name":"Signal","@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"headline":"Nurix Therapeutics, Inc. (NRIX) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Nurix Therapeutics, Inc. (NRIX) Hisse Senedi Yat\u0131r\u0131m\u0131","datePublished":"2025-08-26T06:28:30+00:00","mainEntityOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-nurix-therapeutics\/"},"wordCount":21,"commentCount":0,"image":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-nurix-therapeutics\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals14-scaled.webp","keywords":["signal"],"articleSection":["Signals"],"inLanguage":"tr","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-nurix-therapeutics\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-nurix-therapeutics\/","url":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-nurix-therapeutics\/","name":"Nurix Therapeutics, Inc. (NRIX) Hisseleri Nas\u0131l Al\u0131n\u0131r - Nurix Therapeutics, Inc. (NRIX) Hisse Senedi Yat\u0131r\u0131m\u0131","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-nurix-therapeutics\/#primaryimage"},"image":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-nurix-therapeutics\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals14-scaled.webp","datePublished":"2025-08-26T06:28:30+00:00","author":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"breadcrumb":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-nurix-therapeutics\/#breadcrumb"},"inLanguage":"tr","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-nurix-therapeutics\/"]}]},{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-nurix-therapeutics\/#primaryimage","url":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals14-scaled.webp","contentUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals14-scaled.webp","width":2560,"height":1429},{"@type":"BreadcrumbList","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-nurix-therapeutics\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/pocketoption.com\/blog\/tr\/"},{"@type":"ListItem","position":2,"name":"Nurix Therapeutics, Inc. (NRIX) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Nurix Therapeutics, Inc. (NRIX) Hisse Senedi Yat\u0131r\u0131m\u0131"}]},{"@type":"WebSite","@id":"https:\/\/pocketoption.com\/blog\/tr\/#website","url":"https:\/\/pocketoption.com\/blog\/tr\/","name":"Pocket Option blog","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pocketoption.com\/blog\/tr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"tr"},{"@type":"Person","@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe","name":"Signal","image":{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","caption":"Signal"},"url":"https:\/\/pocketoption.com\/blog\/tr\/author\/signal\/"}]}},"po_author":null,"po__editor":null,"po_last_edited":null,"wpml_current_locale":"tr_TR","wpml_translations":{"vt_VT":{"locale":"vt_VT","id":351900,"slug":"how-to-buy-nurix-therapeutics","post_title":"C\u00e1ch mua c\u1ed5 phi\u1ebfu Nurix Therapeutics, Inc. (NRIX) - \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu Nurix Therapeutics, Inc. (NRIX)","href":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-nurix-therapeutics\/"},"pt_AA":{"locale":"pt_AA","id":351896,"slug":"how-to-buy-nurix-therapeutics","post_title":"Como comprar a\u00e7\u00f5es da Nurix Therapeutics, Inc. (NRIX) - Investimento em a\u00e7\u00f5es da Nurix Therapeutics, Inc. (NRIX)","href":"https:\/\/pocketoption.com\/blog\/pt\/news-events\/signal\/how-to-buy-nurix-therapeutics\/"}},"_links":{"self":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/351903","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/users\/129"}],"replies":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/comments?post=351903"}],"version-history":[{"count":0,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/351903\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/media\/334108"}],"wp:attachment":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/media?parent=351903"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/categories?post=351903"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/tags?post=351903"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}